This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Estimates Moving Higher for Mesa Labs (MLAB): Time to Buy?
by Zacks Equity Research
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bear of the Day: Fresenius Medical (FMS)
by David Bartosiak
Profit estimates are moving in the wrong direction.
Mesa Labs (MLAB) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 107.19% and 10.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -40% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 18.09% and 6.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -40% and 60.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q3 Earnings Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -19.05% and 13.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
Mesa Laboratories and Disney have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mesa Laboratories and Disney have been highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
Mesa Labs (MLAB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 44.96% and 2.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Mesa Labs (MLAB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs, Equinox Gold, General Motors, Tesla and Ford Motor highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mesa Labs, Equinox Gold, General Motors, Tesla and Ford Motor highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division
Mesa Labs (MLAB) Moves 4.5% Higher: Will This Strength Last?
by Zacks Equity Research
Mesa Labs (MLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mesa Labs (MLAB) Lags Q1 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -5.88% and 2.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Mesa Labs (MLAB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 14th
by Zacks Equity Research
CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
Mesa Labs (MLAB) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Lags Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.68% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.